Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Adenocarcinoma
/ diagnosis
Androgen Antagonists
/ pharmacology
Androstenes
/ pharmacology
Antigens, Surface
/ genetics
Cell Line, Tumor
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Gene Expression Regulation, Neoplastic
/ drug effects
Glutamate Carboxypeptidase II
/ genetics
Humans
Male
Oligopeptides
/ pharmacokinetics
PC-3 Cells
Positron Emission Tomography Computed Tomography
/ methods
Prostate-Specific Antigen
/ drug effects
Prostatic Neoplasms
/ diagnosis
Secretory Pathway
/ drug effects
Abiraterone
Androgen antagonist
Prostate cancer
Prostate-specific membrane antigen
VPC-13566
[68Ga]Ga-PSMA-11
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
07
09
2020
accepted:
28
02
2021
pubmed:
25
3
2021
medline:
26
5
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
In recent years, a variety of innovative therapeutics for castration-resistant prostate cancer have been developed, including novel anti-androgenic drugs, such as abiraterone or VPC-13566. Therapeutic monitoring of these pharmaceuticals is performed either by measuring PSA levels in serum or by imaging. PET using PSMA ligands labeled with Fluor-18 or Gallium-68 is the most sensitive and specific imaging modality for detection of metastases in advanced prostate cancer. To date, it remains unclear how PSMA expression is modulated by anti-hormonal treatment and how it correlates with PSA secretion. We analyzed modulation of PSMA-mRNA and protein expression, We found that abiraterone and VPC-13566 upregulate PSMA protein and mRNA expression but block PSA secretion in LNCaP cells. Both anti-androgens also enhanced Our data indicate that PSA secretion and PSMA expression are differentially regulated upon anti-androgen treatment. This finding might be important for the interpretation of
Sections du résumé
BACKGROUND
BACKGROUND
In recent years, a variety of innovative therapeutics for castration-resistant prostate cancer have been developed, including novel anti-androgenic drugs, such as abiraterone or VPC-13566. Therapeutic monitoring of these pharmaceuticals is performed either by measuring PSA levels in serum or by imaging. PET using PSMA ligands labeled with Fluor-18 or Gallium-68 is the most sensitive and specific imaging modality for detection of metastases in advanced prostate cancer. To date, it remains unclear how PSMA expression is modulated by anti-hormonal treatment and how it correlates with PSA secretion.
METHODS
METHODS
We analyzed modulation of PSMA-mRNA and protein expression,
RESULTS
RESULTS
We found that abiraterone and VPC-13566 upregulate PSMA protein and mRNA expression but block PSA secretion in LNCaP cells. Both anti-androgens also enhanced
CONCLUSION
CONCLUSIONS
Our data indicate that PSA secretion and PSMA expression are differentially regulated upon anti-androgen treatment. This finding might be important for the interpretation of
Identifiants
pubmed: 33760944
doi: 10.1007/s00432-021-03583-w
pii: 10.1007/s00432-021-03583-w
pmc: PMC8076114
doi:
Substances chimiques
Androgen Antagonists
0
Androstenes
0
Antigens, Surface
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Prostate-Specific Antigen
EC 3.4.21.77
abiraterone
G819A456D0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1733-1743Références
Ahmadzadehfar H, Wegen S, Yordanova A et al (2017) Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using 177LuLu-PSMA-617. Eur J Nucl Med Mol Imaging 44(9):1448–1454. https://doi.org/10.1007/s00259-017-3716-2
doi: 10.1007/s00259-017-3716-2
pubmed: 28488028
Benešová M, Schäfer M, Bauder-Wüst U et al (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56(6):914–920. https://doi.org/10.2967/jnumed.114.147413
doi: 10.2967/jnumed.114.147413
pubmed: 25883127
Blackburn GF, Shah HP, Kenten JH et al (1991) Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. ClinChem 37(9):1534–1539
Cardinale J, Schäfer M, Benešová M et al (2017) Preclinical Evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med 58(3):425–431. https://doi.org/10.2967/jnumed.116.181768
doi: 10.2967/jnumed.116.181768
pubmed: 27789722
Ceci F, Uprimny C, Nilica B et al (2015) (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42(8):1284–1294. https://doi.org/10.1007/s00259-015-3078-6
doi: 10.1007/s00259-015-3078-6
pubmed: 25975367
Ceci F, Castellucci P, Graziani T et al (2019) 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging 46(1):31–39. https://doi.org/10.1007/s00259-018-4189-7
doi: 10.1007/s00259-018-4189-7
pubmed: 30350010
Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6(Suppl 10):S13–S18
pubmed: 16985927
pmcid: 1472940
Eder M, Schäfer M, Bauder-Wüst U et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. BioconjugChem 23(4):688–697. https://doi.org/10.1021/bc200279b
doi: 10.1021/bc200279b
Emmett L, Yin C, Crumbaker M et al (2019) Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60(7):950–954. https://doi.org/10.2967/jnumed.118.223099
doi: 10.2967/jnumed.118.223099
pubmed: 30552200
Evans MJ, Smith-Jones PM, Wongvipat J et al (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl AcadSci USA 108(23):9578–9582. https://doi.org/10.1073/pnas.1106383108
doi: 10.1073/pnas.1106383108
Ferguson J, Patel D, Atkinson E, Rigsby P, Burns C (2019) Continued provision of WHO International Standards for total and free PSA: content and commutability of replacement preparations. Clin Biochem 71:58–66
doi: 10.1016/j.clinbiochem.2019.07.007
Haese A, Dworschack RT, Piccoli SP, Sokoll LJ, Partin AW, Chan DW (2002) Clinical evaluation of the elecsys total prostate-specific antigen assay on the elecsys 1010 and 2010 systems. Clin Chem 48(6):944–947
doi: 10.1093/clinchem/48.6.944
Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7
doi: 10.1016/S0140-6736(20)30314-7
pubmed: 32209449
Hope TA, Truillet C, Ehman EC et al (2017) 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 58(1):81–84. https://doi.org/10.2967/jnumed.116.181800
doi: 10.2967/jnumed.116.181800
pubmed: 27660139
pmcid: 5209643
Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7(5B):927–935
pubmed: 2449118
Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53(2):227–230
pubmed: 8417812
Kaittanis C, Andreou C, Hieronymus H et al (2018) Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 215(1):159–175. https://doi.org/10.1084/jem.20171052
doi: 10.1084/jem.20171052
pubmed: 29141866
pmcid: 5748857
Kranzbühler B, Salemi S, Umbricht CA et al (2018) Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate 78(10):758–765. https://doi.org/10.1002/pros.23522
doi: 10.1002/pros.23522
pubmed: 29633296
Kranzbühler B, Salemi S, Umbricht CA et al (2019) Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells. Prostate 79(12):1450–1456. https://doi.org/10.1002/pros.23868
doi: 10.1002/pros.23868
pubmed: 31233227
Kuten J, Fahoum I, Savin Z et al (2020) Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med 61(4):527–532. https://doi.org/10.2967/jnumed.119.234187
doi: 10.2967/jnumed.119.234187
pubmed: 31562225
Lallous N, Leblanc E, Munuganti RSN et al (2016) Targeting binding function-3 of the androgen receptor blocks its co-chaperone interactions, nuclear translocation, and activation. Mol Cancer Ther 15(12):2936–2945. https://doi.org/10.1158/1535-7163.MCT-16-0354
doi: 10.1158/1535-7163.MCT-16-0354
pubmed: 27765852
pmcid: 5136324
Lückerath K, Wei L, Fendler WP et al (2018) Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res 8(1):96. https://doi.org/10.1186/s13550-018-0451-z
doi: 10.1186/s13550-018-0451-z
pubmed: 30374743
pmcid: 6206308
Lutz SZ, Hennenlotter J, Scharpf MO et al (2018) Androgen receptor overexpression in prostate cancer in type 2 diabetes. MolMetab 8:158–166. https://doi.org/10.1016/j.molmet.2017.11.013
doi: 10.1016/j.molmet.2017.11.013
Marquette CA, Blum LJ (2008) Electro-chemiluminescent biosensing. Anal BioanalChem 390(1):155–168. https://doi.org/10.1007/s00216-007-1631-2
doi: 10.1007/s00216-007-1631-2
Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 13(4):226–235. https://doi.org/10.1038/nrurol.2016.26
doi: 10.1038/nrurol.2016.26
pubmed: 26902337
Meisenheimer M, Kürpig S, Essler M, Eppard E (2019) Ethanol effects on 68Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing. EJNMMI Radiopharm Chem. https://doi.org/10.1186/s41181-019-0076-1
doi: 10.1186/s41181-019-0076-1
pubmed: 31659535
pmcid: 6779680
Meller B, Bremmer F, Sahlmann CO et al (2015) Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res 5(1):66. https://doi.org/10.1186/s13550-015-0145-8
doi: 10.1186/s13550-015-0145-8
pubmed: 26576996
pmcid: 4648835
Miyamoto DT, Lee RJ, Stott SL et al (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. CancerDiscov 2(11):995–1003. https://doi.org/10.1158/2159-8290.CD-12-0222
doi: 10.1158/2159-8290.CD-12-0222
Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, Gillessen S, Grummet J, Henry AM, Lam TB, Mason MD, van der Kwast TH, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T (2020) EAU guidelines: prostate cancer 2020. Accessed 25 May 2020
Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC (2015) Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 75(3):242–254. https://doi.org/10.1002/pros.22910
doi: 10.1002/pros.22910
pubmed: 25327687
Paller CJ, Piana D, Eshleman JR et al (2019) A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate 79(14):1597–1603. https://doi.org/10.1002/pros.23883
doi: 10.1002/pros.23883
pubmed: 31361358
pmcid: 6818502
Rahbar K, Afshar-Oromieh A, Seifert R et al (2018) Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45(12):2055–2061. https://doi.org/10.1007/s00259-018-4089-x
doi: 10.1007/s00259-018-4089-x
pubmed: 30027419
pmcid: 6182394
Rao K, Liang S, Cardamone M et al (2018) Cost implications of PSA screening differ by age. BMC Urol 18(1):38. https://doi.org/10.1186/s12894-018-0344-5
doi: 10.1186/s12894-018-0344-5
pubmed: 29743049
pmcid: 5944051
Richards J, Lim AC, Hay CW et al (2012) Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72(9):2176–2182. https://doi.org/10.1158/0008-5472.CAN-11-3980
doi: 10.1158/0008-5472.CAN-11-3980
pubmed: 22411952
pmcid: 4281708
Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO (2008) 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate 68(7):773–783. https://doi.org/10.1002/pros.20739
doi: 10.1002/pros.20739
pubmed: 18247401
Soifer HS, Souleimanian N, Wu S et al (2012) Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J BiolChem 287(6):3777–3787. https://doi.org/10.1074/jbc.M111.261933
doi: 10.1074/jbc.M111.261933
Umbricht CA, Benešová M, Schmid RM et al (2017) 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res 7(1):9. https://doi.org/10.1186/s13550-017-0257-4
doi: 10.1186/s13550-017-0257-4
pubmed: 28102507
pmcid: 5247395
van den Broeck T, van den Bergh RCN, Arfi N et al (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. EurUrol 75(6):967–987. https://doi.org/10.1016/j.eururo.2018.10.011
doi: 10.1016/j.eururo.2018.10.011
Wallace TJ, Torre T, Grob M et al (2014) Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer 5(1):3–24. https://doi.org/10.7150/jca.7709
doi: 10.7150/jca.7709
pubmed: 24396494
pmcid: 3881217
Wright GL, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48(2):326–334. https://doi.org/10.1016/s0090-4295(96)00184-7
doi: 10.1016/s0090-4295(96)00184-7
pubmed: 8753752
Wüstemann T, Haberkorn U, Babich J, Mier W (2019) Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy. Med Res Rev 39(1):40–69. https://doi.org/10.1002/med.21508
doi: 10.1002/med.21508
pubmed: 29771460